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Abstract
Background:  The prebiotic potential of lactulose is well established and preclinical studies
demonstrated a protective effect of lactulose in murine models of colitis. The aim of the present
study was to investigate the clinical and histological efficacy of lactulose in patients with
inflammatory bowel disease (IBD), for which probiotic therapy yielded promising results.
Methods: Patients were treated with standard medication alone or combined with 10 g lactulose
daily as adjuvant therapy for 4 months. Clinical efficacy of treatment was assessed using clinical
activity indices, a quality of life index (IBDQ), endoscopic scores, defecation frequency and
monitoring corticosteroid medication. Orsomucoid, alpha1-antitrypsin and other laboratory
parameters were determined. In addition, in some participants colonic biopsies were analyzed with
haematoxylin-eosin staining or with antibodies against HLA-DR, CD68, IgA and CD3, and evaluated
systematically. All measurements were performed both at enrolment and at the end of the trial.
Results: 14 patients presenting ulcerative colitis (UC) and 17 patients presenting Crohn's disease
(CD), most of them in a clinically active state, were enrolled in this pilot study. After 4 month no
significant improvement of clinical activity index, endoscopic score or immunohistochemical
parameters was observed in CD or UC patients receiving lactulose in comparison to the control
group. However, significant improvement of quality of life was observed in UC patients receiving
lactulose compared to the control group (p = 0.04).
Conclusion: The findings of the present pilot study indicate that oral lactulose has no beneficial
effects in IBD patients in particular with regard to clinical activity, endoscopic score or
immunohistochemical parameters. The importance of the beneficial effect of lactulose in UC
patients regarding the quality of life needs further evaluation in larger controlled clinical trials.
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Background
Inflammatory bowel diseases (IBD), commonly referred
to as Crohn's disease (CD) and ulcerative colitis (UC) are
recurrent aggressive inflammatory conditions of multifac-
torial etiology, which to date are not well understood.
Interactions of genetic background, disturbance of the
mucosal barrier, dysregulation of intestinal immune
responses as well as bacterial and other environmental
factors were found to play a role in the development of
IBD.
In this context, the mucosal barrier is a key factor, since its
disturbance usually precedes the onset of IBD [1]. At the
same time, a change of intestinal flora can be detected,
specifically with regard to adherent bacteria [2,3]. In ani-
mal models of colitis, it has been shown that IBD does not
develop in a germ-free environment [4]. In human ulcer-
ative colitis, exacerbations of intestinal inflammation can
be prevented by probiotic bacteria, possibly because they
inhibit pathogenic bacteria by either growth or adherence
inhibition and competition, respectively [5].
Previous medical treatment of IBD has predominantly
focused on nonspecific suppression of the inflammatory
process. Antibiotics can selectively decrease tissue inva-
sion of bacteria and eliminate aggressive bacterial species
[6]; however, such treatment is not sustaining and often
accompanied by substantial side effects. The alteration of
the intestinal flora by probiotics (beneficial bacterial spe-
cies) and prebiotics (poorly absorbed dietary oligosaccha-
rides) may offer an alternative therapeutic approach. Such
substances are capable of modulating the intestinal flora
in IBD, resulting in a predominance of beneficial Lactoba-
cillus and Bifidobacterium species and in clinical benefit
[7,8].
Some controlled clinical trials have been conducted
regarding probiotic therapy in UC, showing that the pro-
biotic bacterial mixture VSL#3 is effective in preventing
pouchitis [9-11], and that the probiotic E. coli Nissle 1917
prevents relapses of active UC [12-14]. In CD, probiotic
trials yielded inconsistent results [15-20]. A few pilot stud-
ies suggested that E. coli Nissle 1917 is beneficial in taper-
ing steroids in CD [15], that Lactobacillus  GG may be
effective in children with CD [16,17], and that Saccharo-
myces boulardii may be beneficial in adult CD [18,19].
Prebiotics stimulate the growth and metabolism of pro-
tective commensal enteric bacteria, as well as the produc-
tion of short chain fatty acids. The net result of prebiotic
administration is theoretically similar to administering
probiotic bacteria, however, the effect of prebiotics on the
patient's flora can continue for several weeks after cessa-
tion of treatment [21], while the effect of probiotics is gen-
erally shorter. To date, only a few clinical trials on
prebiotics in IBD have been conducted. In one open-label
trial, prebiotic germinated barley foodstuff was shown to
reduce clinical and endoscopic activity in patients with
UC [22]. The prebiotic potential of lactulose is well estab-
lished [23]. In murine models of colitis, lactulose
decreases the number of adherent and translocated bacte-
ria as well as histologically detectable inflammation [24].
Furthermore, lactulose ameliorated DSS-induced colitis in
rats in a dose-dependent manner [25].
In summary, trials in both experimental colitis and
human IBD suggest a potential role of probiotic bacteria
and prebiotic products for treatment of IBD. The aim of
the present study was to investigate clinical effects of lac-
tulose in IBD patients in a pilot study to further assess if
there is a rationale for large scale clinical trials. In addi-
tion, immunohistochemical tests were performed to study
the potential effect of lactulose on mucosal cell infiltra-
tion.
Methods
Patients and study design
52 patients of the Department of Gastroenterology at the
Hannover Medical School were recruited and randomised
between August 2000 and July 2003. The study was
approved by the Ethical Committee of the Hannover Med-
ical School. All procedures were in accordance with the
Declaration of Helsinki. To be included in the trial,
patients had to present IBD. In most of them the clinical
activity was confirmed by elevated Clinical Activity Index
(CAI) scores in UC or elevated Crohn's Disease Activity
Index (CDAI) scores. The diagnosis of IBD was confirmed
by classical clinical and endoscopic means according to
the German and Austrian guidelines for UC and CD [26-
28]. Clinical parameters were obtained from all patients.
In addition to the clinical parameters in some patients
immunohistochemical parameters were analyzed. There-
fore biopsies were collected and analyzed at enrolment
and at the end of the study.
The trial was conducted as a prospective, randomised and
controlled pilot study with a parallel-group design.
Patients in the control group received standard medica-
tion according to the recommendations of the guidelines
[29-31]. Patients in the lactulose group received standard
medication plus 15 ml lactulose syrup (containing 10 g
lactulose) daily as adjuvant therapy. All investigations
were performed at enrolment and at the end of the 4-
months trial period.
Evaluation of clinical efficacy
Clinical activity indices
Well-established activity indices were used to assess the
activity of the inflammatory process. For UC, we
employed the CAI according to Rachmilewitz [32]. HighBMC Gastroenterology 2007, 7:36 http://www.biomedcentral.com/1471-230X/7/36
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point CAI-scores correspond with a high activity of
inflammation, with remission being defined as a CAI
score of ≤ 4. Since erythrocyte sedimentation rate (ESR) is
not routinely measured at our hospital, C-reactive protein
(CRP) values reflecting similar activity were used as a
proxy [33]. For CD the CDAI according to Best [34] and
the Severity and Activity Index (SAI) was used [35]. High
point CDAI scores indicate a high activity of inflamma-
tion, a decrease of more than 100 points implies clinical
improvement, and remission is defined as a CDAI score of
≤ 150 [36]. In addition, Defecation frequency was docu-
mented by all patients over a period of one week using an
appropriate diary for evaluation of clinical activity of the
disease.
Quality of life index
To assess quality of life, the German version of the Inflam-
matory Bowel Disease Questionnaire (IBDQ) was used
[37]. It includes 32 questions concerning mood, pain, and
limitations in daily life. Scores between 32 and 224 points
may be reached. High values indicate a better quality of
life, and remission is defined as an IBDQ score of > 190.
All questionnaires were completed by the patients retro-
spectively at presentation.
Medication
To assess clinical efficacy, required corticosteroid medica-
tion was documented semiquantitatively (no corticoster-
oids/≤ 5 mg prednisolone equivalent/> 5 mg
prednisolone equivalent).
Endoscopic scores
Local inflammation was assessed by endoscopic scores
using an ordinal scale, high values indicating high activity
of inflammation. For UC the Baron Scale, discriminating
normal mucosa/erythem/erosions/ulcerations and spon-
taneous bleeding was applied, with scores ranging from 0
to 3 points [38]. For CD a score similar to the Rutgeerts
Score was used, assessing criteria such as normal mucosa/
< 5 aphthae/> 5 aphthae or skip lesions/diffuse aphthae/
diffuse inflammation with ulcerations, nodules, and stric-
tures, with scores ranging from 0 to 4 points [39].
Laboratory parameters
In addition to clinical findings, a standard set of labora-
tory parameters was used to assess disease state and/or
activity.
In blood, haemoglobin (Hb) and haematocrit values were
determined to calculate activity indices. From serum, we
determined orsomucoid (Ors), albumin (Alb), and the
immunoglobulins IgG, IgA and IgM. The "Factor Score"
was calculated according to the formula 1/2 × Hb (g/dl) +
Alb (g/l) - 4 × Ors (g/l) - 37. Positive values indicate remis-
sion, negative values indicate an acute episode of inflam-
mation [40].
In feces samples, α1-antitrypsin and the pH were meas-
ured. The α1-antitrypsin concentration is a marker for
intestinal loss of protein and impaired intestinal permea-
bility. In CD patients, this marker has been established as
an activity marker [41]. The pH measurements were used
to verify patient compliance, since lactulose administra-
tions causes a decrease in fecal pH values [21].
Histological and immunohistochemical evaluation
During colonoscopy or surgical intervention, mucosal
biopsies of a size of 1 × 1 × 2 mm3 were taken from areas
showing maximal inflammation. Haematoxylin-eosin
(HE) stainings and immunohistochemical (IHC) stain-
ings were performed.
For each biopsy the percentages of lamina propria eosi-
nophils and neutrophils as well as of intraepithelial lym-
phocytes were assessed. To evaluate the inflammatory
activity, a HE Score including epithelial integrity, mucosal
architecture, mononuclear cell infiltration, neutophil-
granulocytic cell infiltration and crypt abscesses was calcu-
lated analogous to the scoring system for IBD described by
Geboes et al. [42]. High points correspond with high
inflammatory activity.
Immunohistochemical stainings were performed using
the labeled-streptavidin-biotin (LSAB) method for deter-
mination of mucosal counts of T-cells, IgA-producing cells
and macrophages as well as the extent of cell activation.
Primary antibodies included (1) anti-CD3 (monoclonal
mouse IgG2a, Biocarta, Hamburg, Germany) to mark
mucosal T lymphocytes, (2) anti-IgA antibody (α-Heavy
Chain) Ab-1 (monoclonal mouse IgG1κ, Biocarta, Ham-
burg, Germany) to identify IgA producing plasma cells,
(3) anti-CD68 (monoclonal mouse IgG1κ, Zymed Lab.,
San Francisco, USA) to detect macrophages and (4) anti-
human HLA-DR (monoclonal mouse IgG1κ, DAKO,
Glostrup, Denmark), a general marker of cell activation
[43-46]. Human-absorbed, biotinylated, affinity-purified
secondary antibodies were introduced according to man-
ufacturer instructions (Histostain-Plus Kit, Zymed, San
Franzisco, USA). Slides were counterstained with Mayer's
haemalaun (Merck, Darmstadt, Germany). For each stain-
ing, an appropriate isotype control antibody was
included. To calculate the percentage of CD68, IgA and
CD3, one thousand lamina propria cells per biopsy were
counted. The evaluation of HLA-DR expression was per-
formed semiquantitatively since it was not possible to dif-
ferentiate between all individual cells. The
semiquantitative analysis was performed using a score
adapted from Beaugerie et al [47]. All counts were per-
formed in a blinded manner by the same investigator.BMC Gastroenterology 2007, 7:36 http://www.biomedcentral.com/1471-230X/7/36
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Statistics
Data are presented as means ± standard error of the mean
(SEM), unless indicated otherwise. Mann-Whitney-U test
were used to evaluate the comparability of the study
groups at baseline. To compare the data of the lactulose
group with those from the control group, the difference of
the mean values (value at the end of the study minus value
at the start of the study) for each group was calculated. For
comparison, the unpaired T-Test was employed. The T-test
for paired samples was used to uncover potential differ-
ences between mean values at start and end of the study.
The statistical analysis of ordinal data (histological and
immunohistological data) was performed using the
Mann-Whitney-U test for unpaired samples and the Wil-
coxon matched pairs test for paired groups. A p ≤ 0.05 was
considered significant, p values > 0.05 to 0.10 were inter-
preted as tendencies. All statistical analysis was performed
using the software package SPSS 12.0.
Results
Study population
A total of 31 IBD patients completed the study according
to protocol, 14 of whom presented UC, and 17 CD. 7 UC
and 8 CD patients had been randomly assigned to the lac-
tulose groups (L), with the remaining 7 UC and 9 CD
patients belonging to the control groups (C) (Figure 1).
The majority of patients enrolled in this study were hospi-
talized because of symptoms of active disease. 5 patients
enrolled in this study (4 UC patients of the control group
and 1 UC patient of the lactulose group) were ambulant
patients who came because of symptoms and underwent
a colonoscopy. Demographic and clinical characteristics
of the patients at baseline are shown in table 1. The partic-
ipants received standard medication during the whole
study. Medication at baseline is also shown in table 1.
Duration of participation among the different groups
show no statistical differences. In addition to the clinical
parameters in 20 patients, 9 of whom presented UC the
effect of oral lactulose on immunohistochemical parame-
ters was analyzed. Therefore biopsies were collected and
analyzed at enrolment and at the end of the study.
Table 1: Baseline characteristics of the study groups
Ulcerative colitis Crohn's disease
Lactulose (n= 7) Control (n= 7) Lactulose (n= 9) Control (n= 8)
Age* 38.8 ± 12.4 38.1 ± 8.8 30.7 ± 7.0 33.5 ± 11.7
Female sex 3 4 5 4
Disease duration (years)* 8.3 ± 12.2 9.3 ± 5.0 5.0 ± 5.4 6.7 ± 9.8
Disease Activity (CAI/CDAI)* 10.3 ± 5.9 10.4 ± 11.2 195.5 ± 148.4 273.9 ± 112.9
IBDQ* 123 ± 47.0 132 ± 58.4 136 ± 42.7 134 ± 43.3
Defecation/week* 37 ± 24.3 36 ± 24.1 39 ± 30.4 45 ± 23.3
Duration of participation* 3.7 ± 1.5 4.8 ± 2.5 5.0 ± 3.1 4.3 ± 2.2
Medication
Prednisolone equivalents > 5 mg 5 2 6 6
Prednisolone equivalents ≤ 5 mg 0 0 1 3
5-ASA 7 4 6 3
Immunosuppressive drugs 1 1 3 2
Antibiotics 0 3 5 4
*(Mean ± SD)
Study design Figure 1
Study design. *Criteria for exclusion of patients were: out 
of reach (10), surgery (4), protocol too demanding (3), drug 
intake not reliable (3), different study during study period (1).BMC Gastroenterology 2007, 7:36 http://www.biomedcentral.com/1471-230X/7/36
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Clinical data
Clinical activity indices
No significant improvement of clinical activity index was
observed in CD (p > 0.1) or UC (p = 0.092) patients
receiving lactulose in comparison to the control group
(Figure 2). In UC, clinical activity of the disease could be
reduced within the lactulose group. In this group, the CAI
improved by 5.6 ± 2.3 from 10.3 ± 2.2 to 4.7 ± 1.8 (p =
0.047), and 4 out of 7 patients reached remission. In the
control group, the CAI did not change (start of therapy
10.4 ± 4.2, end of study 9.3 ± 3.6), none of 4 patients with
active disease reached remission (Figure 2). In CD, both
the CDAI and SAI showed improvement only in the con-
trol group. Without lactulose, CDAI improved by 125 ±
39 from 274 ± 38 to 149 ± 32 (p = 0.013), SAI improved
by 95 ± 28 from 216 ± 34 to 122 ± 26 (p = 0.009). In the
lactulose group, the CDAI did not change significantly
(start of therapy 196 ± 53, end of study 163 ± 42) (Figure
3).
Quality of life index
In the UC lactulose group, the IBDQ score increased by 48
± 14 from 123 ± 20 to 171 ± 18 (p = 0.026), in contrast,
the IBDQ did not change significantly in the UC controls
(start of therapy 132 ± 24, end of study 138 ± 22). The
improvement in the lactulose group proved to be statisti-
cally significant compared to controls (p = 0.037). In CD,
IBDQ increased by 24 ± 12 from 136 ± 15 to 160 ± 17 (p=
0.089) in the lactulose group, and by 37 ± 19 from 134 ±
17 to 171 ± 16 (p = 0.098) in the control group (Figure 4).
Quality of Life Figure 4
Quality of Life. Assessment of a standardized and validated 
IBD questionnaire, evaluated by IBDQ (IBDQ, see Methods), 
consisting of 32 questions for mood, pain, and limitations in 
daily life. High values indicate a better quality of life; remis-
sion is defined as an IBDQ score of > 190. Means ± SEM for 
baseline and final scores after 4 months of supplementary lac-
tulose therapy versus standard medication alone are shown. 
*Not all patients responded to the questionnaire.
Clinical activity in ulcerative colitis Figure 2
Clinical activity in ulcerative colitis. The clinical activity 
index (CAI) was assessed. Values below 4 (dotted line) indi-
cate remission. Baseline and final scores after 4 months of 
supplementary lactulose therapy versus standard medication 
alone are shown.
Clinical activity in Crohn's disease Figure 3
Clinical activity in Crohn's disease. Clinical activity was 
measured using the CDAI and SAI scores (see Methods). 
Remission is indicated by a CDAI ≤ 150 (dotted line). Base-
line and final scores after 4 months adjuvant lactulose ther-
apy (lactulose) versus standard medication alone (control) is 
shown.BMC Gastroenterology 2007, 7:36 http://www.biomedcentral.com/1471-230X/7/36
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Medication
During the study period, corticosteroid medication could
be reduced in many patients. While 4 of 5 UC patients
receiving corticosteroids in the lactulose group could
reduce their corticosteroid medication (p = 0.063), 1 of 2
UC patients in the control group could reduce it. In CD, 1
of 7 patients receiving corticosteroids in the lactulose
group could reduce the dosage of corticosteroids, while
one had to increase it, compared to 3 of 9 patients who
could reduce their medication in the control group. How-
ever, there were no significant differences between the
groups.
Endoscopic scores
The endoscopic scores showed no change between the
treatment groups (CD control group from 2.3 ± 0.9 to 2.4
± 0.9, lactulose group 2.6 ± 0.7 to 1.8 ± 1.1; UC control
group from 1,7 ± 0,6 to 2,4 ± 0,4, lactulose group from 1,4
± 0,5 to 2.0 ± 0.0)
Defecation frequency
No significant change in defecation rate was found for the
UC groups. In CD, defecation rate showed a trend to
decrease both in the lactulose group by 16 ± 7 from 39 ±
11 to 24 ± 8 (p= 0.063), and in the control group by 20 ±
10 from 45 ± 8 to 24 ± 6 (p= 0.069). (Figure 5).
Safety
Four out of 15 patients receiving lactulose had minor side
effects. In UC, one patient reported an increased defeca-
tion frequency and slight flatulence, another suffered
from abdominal pain because of meteorism. In CD, one
patient reported on slight flatulence; another one on
decreased stool consistency. Despite these facts all
patients completed the study according to protocol.
Laboratory parameters
Blood
Immunoglobulin (Ig) concentrations in UC and CD
patients were not changed by lactulose (table 2). The Fac-
tor score defined in the 'Method' section showed improve-
ments in both CD groups (Lactulose group: by 8.4 ± 3.0
from -7.0 ± 3.1 to 1.3 ± 2.6 (p = 0.044); Control group: by
6.0 ± 2.5 from -4.7 ± 3.1 to 1.3 ± 2.0 (p = 0.028); however,
there was no statistically significant difference between
the treatment groups (table 2).
Feces
In UC treated with lactulose, α1-antitrypsin concentration
decreased (UC/L: -41.8 ± 15.6 from 69.5 ± 17.6 mg/dl to
27.8 ± 9.0 mg/dl; p = 0.076). In UC control, no change
was observed (UC/C: +7.9 ± 15.4 mg/dl; n. s.). In CD, the
control group showed a decrease by -31.4 ± 9.5 mg/dl
from 66.5 ± 9.7 mg/dl to 35.2 ± 11.4 mg/dl (p = 0.016).
In the lactulose group we found a similar tendency, albeit
not statistically significant (table 2). Differences between
the treatment groups did not prove to be statistically sig-
nificant. pH values tended to increase in the UC lactulose
group, but not in the respective control group (table 2).
Table 2: Developing of blood and fecal parameters
Ulcerative colitis Crohn's disease
Lactulose (n= 7) Control (n= 7) Lactulose (n= 9) Control (n= 8)
Immunoglobulin G (g/l)*
Before 12.3 ± 1.3 14.0 ± 2.0 12.9 ± 4.6 11.8 ± 3.4
After 12.9 ± 1.2 13.3 ± 2.0 11.8 ± 4.5 11.6 ± 4.1
Immunoglobulin A (g/l)*
Before 3.0 ± 0.5 2.8 ± 0.4 4.6 ± 3.4 3.6 ± 1.1
After 3.0 ± 0.7 2.3 ± 0.3 4.3 ± 3.4 3.6 ± 1.3
Immunoglobulin M (g/l)*
Before 1.9 ± 0.2 2.4 ± 0.8 1.9 ± 1.7 1.7 ± 0.5
After 2.1 ± 0.4 2.3 ± 0.7 1.9 ± 1.7 1.8 ± 1.0
Blood activity factor*,†
Before -2.9 ± 1.9 2.9 ± 2.4 -7.0 ± 3.1 -4.7 ± 3.1
After 5.4 ± 2.8 5.7 ± 1.2 1.3 ± 2.6‡ 1.3 ± 2.0‡
Fecal α1-antitrypsine*
Before 69.5 ± 17.6 56.8 ± 14.4 79.8 ± 9.9 66.5 ± 9.7
After 27.8 ± 9.0 50.0 ± 12,7 55.3 ± 14.1 35.2 ± 11.4‡
Fecal pH*
Before 6.4 ± 0.2 6.8 ± 0.1 6.8 ± 0.2 6.7 ± 0.7
After 7.0 ± 0.3 6.8 ± 0.1 6.6 ± 0.4 6.6 ± 0.7
* (Mean ± SEM)
† Factor score: 1/2 × Hb (g/dl) + Alb (g/l) - 4 × Ors (g/l) - 37.
‡ p < 0.05 in comparison to the baselineBMC Gastroenterology 2007, 7:36 http://www.biomedcentral.com/1471-230X/7/36
Page 7 of 11
(page number not for citation purposes)
Histological and immunohistological data
Haematoxylin-eosin (HE) staining
The percentage of eosinophils in relation to intestinal
lamina propria cells showed a tendency to decrease in the
control group of UC (p = 0.066). In CD, the control group
showed a significant increase (p = 0.028), but no consist-
ent changes were observed in the lactulose group (Figure
6A). The percentage of neutrophils, intraepithelial lym-
phocytes and the HE score did not show consistent
changes during the study period and no statistically signif-
icant differences could be found between the groups.
Immunohistological staining
The number of CD3 positive cells decreased in CD
patients in the course of the study, reaching significance in
the control group (p = 0.028), but not in the lactulose
group (p= 0.068). No consistent changes were observed in
UC (Figure 6B). Analysis of CD68+ and Ig A+ cells as well
as HLA-DR expression revealed no significant changes
related to the supplementary lactulose treatment.
Discussion
The present pilot study was conducted to investigate clin-
ical and immunohistological effects of lactulose in IBD
patients. Maybe due to the low number of patients
enrolled in this study no beneficial effects in IBD patients
with regard to clinical activity, endoscopic score, serum
markers, or immunohistochemical parameters could be
observed. However, quality of life index (IBDQ) was
improved by lactulose at a dosage of 10 g per day as adju-
vant therapy to standard medication in UC patients. Since
this pilot study is not a placebo controlled study, we can
not rule out a placebo effect in the lactulose group. The
beneficial effect in clinical activity in UC patients within
the lactulose group is subject to review in larger trials.
Previous clinical studies report substantial benefit of par-
ticular pre- and probiotics in UC [9-14], but not in CD
[15-20]. Fellermann et al. [48] described a defensin defi-
ciency in IBD, which could lead to an impaired intestinal
barrier function and subsequently to the initiation of IBD.
In UC, defensins are reversibly down-regulated for
unknown reasons, whereas in CD, defensin expression is
permanently impaired because of genetic alterations.
Therefore, probiotics such as E.coli Nissle 1917 can reverse
the decrease in defensin expression in UC, but not in CD.
Possibly, lactulose, similarly to the probiotic, could also
upregulate defensin expression provided that no genetic
Bowel movements Figure 5
Bowel movements. Frequency of defecation in UC and CD per week in the lactulose group (L) and control group (C). Base-
line and final numbers after 4 months supplementary lactulose therapy versus standard medication alone are shown.BMC Gastroenterology 2007, 7:36 http://www.biomedcentral.com/1471-230X/7/36
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mutations have occurred. These mechanisms fit with the
observations of Szilagyi et al. [49] who reported that lac-
tulose had a less pronounced effect on the intestinal flora
in IBD patients than in healthy controls. In particular, UC
patients showed a trend towards adaptation of the colonic
flora, while no adaptation was observed in CD. This is
likely caused by an increased intestinal permeability,
resulting in lactulose absorption, which could further
explain the ineffectiveness of lactulose in CD.
The clinical benefit we observed in UC within the lactu-
lose group was not confirmed on the endoscopic level,
possibly because the correlation between endoscopic
scores and clinical activity is known to be weak. In CD,
only one third of patients with corticosteroid-induced
Immunohistochemistry Figure 6
Immunohistochemistry. Eosinphil granulocytes (panel A) and CD3 positive lymphocytes (panel B), expressed as percentage 
of lamina propria cells, were quantified in UC and CD. Baseline and final values after 4 months of supplementary lactulose 
treatment (L) versus standard medication (controls, C) alone are shown.BMC Gastroenterology 2007, 7:36 http://www.biomedcentral.com/1471-230X/7/36
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clinical remission gained normalisation of the endoscopic
changes [50], whereas in UC, this correlation is known to
be closer [51]. Moreover, one should consider the fact that
an endoscopically normal intestine can still present
microscopic inflammatory alterations [52].
It is important to note that the defecation frequency was
not different between the lactulose groups and controls.
Considering the laxative effect of lactulose in constipation
[53], an increase of defecation rates could have been
expected in the lactulose groups. Instead, we observed a
trend towards decreased bowel movements in all CD
patients, independent of the lactulose medication. In UC
patients, the number of bowel movements did not
change, neither in the lactulose group nor in the control
group. We therefore conclude that at dosages adminis-
tered here (10 g/d), lactulose does not increase defecation
rates in IBD patients. Four out of 15 patients experienced
some mild to moderate side effects possibly related to lac-
tulose (2× flatulence, 1× increase in the number of bowel
movements, 1× both). Overall, the administered dosage
of lactulose was well tolerated, with no serious adverse
effects being observed.
Laboratory parameters (biochemical and immunohisto-
logical markers) yielded only few conclusive results. Lac-
tulose was reported to modify systemic immune
responses in a murine model; however, such findings
were not confirmed by our immunoglobulin measure-
ments. Interestingly, eosinophil counts in the mucosa
were elevated in UC patients receiving lactulose, but not
in the corresponding control group. In recent studies,
eosinophilia has been associated with healing phases fol-
lowing chronic inflammation. In CD, we made an oppo-
site observation, once more confirming the clinical data
that suggested benefit of lactulose only in UC. Other his-
tological and immunohistochemical data were inconclu-
sive or could not be clearly related to the additional
treatment with lactulose.
A critically issue of the study is the variation between the
groups in prestudy clinical characteristics. For example,
the high dosis of prednisolon in 5 UC patients receiving
lactulose compared to 2 patients of the control group. The
dosis of prednisolon has been changed directly before
enrollment in the study. On this account, we can not
exclude that the medication is an additional reason for the
observed improvement within the lactulose group in UC
patients.
Conclusion
In conclusion, our present pilot study indicates that oral
lactulose has no beneficial effects in IBD patients. For
sure, a randomized placebo-controlled trial is currently
underway to confirm these observations.
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